Drug Discovery Institute
At Alzheimer’s Research UK, we are committed to finding treatments that slow or stop the diseases that cause dementia.
We won’t stop until we find them.
A highlight of the conference, in which so much was covered, was a presentation from Dr John Skidmore, Chief Scientific Officer at our Cambridge Drug Discovery Institute (DDI).
Dr John Davis is the new Chief Scientific Officer at the Alzheimer’s Research UK Oxford Drug Discovery Institute.
As Chief Scientific Officer, Prof Paul Whiting will drive the progress of the Drug Discovery Institute.
The Alzheimer’s Research UK Drug Discovery Alliance is a £30m powerhouse of dementia treatment discovery at leading universities for dementia research.